BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

Despite the challenge of introducing a drug to the market during the COVID-19 pandemic, sales of nearly all new product launches increased in 2Q20 versus 1Q, with drugs to treat life-threatening conditions and oral products...
BioCentury | Mar 21, 2019
Company News

FDA approves Jazz's Sunosi for daytime sleepiness

FDA approved late Wednesday Sunosi solriamfetol from Jazz to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) expects to launch Sunosi following a...
BioCentury | Mar 9, 2018
Clinical News

Jazz gets PDUFA date for excessive sleepiness candidate

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said FDA accepted for review an NDA for solriamfetol (JZP-110) to treat excessive sleepiness associated with narcolepsy or obstructive sleep apnea. The PDUFA date is Dec. 20. Solriamfetol is a phenylalanine...
BioCentury | Aug 31, 2017
Translation in Brief

Mouse model herds

With the publication of its first set of data, the International Mouse Phenotyping Consortium (IMPC) has demonstrated it's making strides toward generating and characterizing the phenotypes of knockout models corresponding to the entire mouse genome...
BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Jun 17, 2013
Clinical News

ADX-N05: Phase IIa data

A double-blind, placebo-controlled, crossover, U.S. Phase IIa trial in 33 patients with narcolepsy showed that once-daily ADX-N05 met the primary endpoint of increasing sleep latency from baseline to week 2 as measured by the MWT...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Platelet derived growth factor A (PDGFA; PDGF1) A study in mice suggests lithium could help treat neonatal hydrocephalus, an expansion of the cerebral ventricles....
Items per page:
1 - 10 of 24